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A 2-year-old, 12 kg, intact male crossbreed dog was presented with respiratory distress,
exercise intolerance, and gagging. Plain thoracic radiographs revealed severe pleural
effusion. Although bilateral needle thoracocentesis and chest tube placement were
performed, no re-expansion of the lung lobes occurred. Pleural effusion was of chylous
quality and led to lung entrapment. Computer tomography revealed a highly atrophic
and atelectatic right middle lung lobe. The remaining lung lobes were only expanded to
∼40%. Visceral pleura and pericardium showed a heterogeneous thickening consistent
with pleural fibrosis. Partial pericardiectomy with resection of the middle lung lobe
through a right lateral thoracotomy was performed. Ligation of the thoracic duct and
ablation of the cisterna chyli was achieved through a single paracostal approach.
Histopathology revealed chronic-active proliferative beginning granulomatous pleuritis,
fibrotic pericarditis, and partial coagulative necrosis with incomplete granulomatous
sequestration in the resected middle lung lobe. Chylothorax resolved after surgical
intervention. Active pleural effusion resolved, and lung entrapment changed to trapped
lung disease. The remaining lung lobes re-expanded to ∼80% over the following 6 days.
The dog was discharged 10 days later. Mild to moderate pleural effusion of non-chylic
quality was present during the following 4 months. Meloxicam was administered for 4
months because of its anti-fibrotic and anti-inflammatory properties. Fifteen months later,
thoracic radiographs revealed full radiologic expansion of the lungs with persistent mild
pleural fibrosis. To the authors’ knowledge, this is the first case report of pneumothorax
due pleural fibrosis caused by chylothorax in a dog with an excellent clinical outcome.
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BACKGROUND
Pleural fibrosis is a rarely described pathological condition in dogs and cats. To the authors’
knowledge, only 5 canine and 22 feline cases have been reported (Table 1). Previously, this
condition was termed constrictive pleuritis. Due to pleural inflammation, a progressive constriction
of lung parenchyma occurs, called lung entrapment. This condition may result in severe
respiratory distress (6). In general, pleural fibrosis results from inflammatory processes within
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the thoracic cavity combined with active pleural effusions.
Chylothorax and hemothorax are described in dogs with pleural
fibrosis (Table 1). Radiologically, pleural fibrosis should be
suggested if the lungs appears rounded accompanied with pleural
effusion or if pneumothorax occurs after thoracocentesis (9).
Decortication is recommended in case of severe respiratory
distress. Complications like pneumothorax, tracheal tears, re-
expansion pulmonary edemas, or death may occur (5, 7, 10).
Anti-inflammatory doses of prednisone were given in cats with
severe pleural fibrosis. The results were variable (6). However,
prognosis in dogs and cats with pleural fibrosis is poor. In the
literature, mortality rate in dogs and cats amounts 70% (17/24
dogs and cats with known outcome; Table 1).
The aim of this case report is to describe clinical presentation,
imaging alterations, treatment and outcome in a dog with
pneumothorax caused by pleural fibrosis after chylothorax.
CASE PRESENTATION
A 2-year-old, weighing 12 kg, intact male crossbreed dog
was referred to the Small Animal Clinic at Freie Universität
Berlin with respiratory distress over the past 5 days. The
owners observed a reduced appetite, exercise intolerance and
gagging 2 weeks prior to admission. Pre-treatment with
amoxicillin/clavulanic acid (20 mg/kg q12h PO) for 3 days
was initiated by the referring veterinarian, but no clinical
improvement occurred.
On presentation, the dog showed moderate tachypnea with
a resting respiratory rate of 60 breaths per minute. Thoracic
auscultation revealed muﬄed heart and significantly reduced
lung sounds in the ventral thorax. On both thoracic sides,
percussion produced a dampened, hyporesonant sound. All
other clinical parameters were unremarkable. Hematology and
blood chemistry were unremarkable with the exception of mild
leukocytosis (19.2∗109/L, reference interval [RI] 5.6–14.0∗109/L)
and thrombocytosis (456∗109/L, RI 165–400∗109/L).
Stabilization was initialized with oxygen supplementation by
mask with a flow rate of 2 L/min. Pulse oximetry revealed
a SpO2 of 80%. The dog was sedated with butorphanol
(Butorgesic, cp-pharma R©, 0.3 mg/kg IV) and midazolam
(Midazolam-ratiopharm R©, 15 mg/3ml, 0.2 mg/kg IV). After
initial stabilization, a left sided thoracic radiograph revealed
severe pleural effusion (Figure 1A).
750ml on the left and 600ml on the right thoracic side
of a white-milky fluid was aspirated by needle thoracocentesis
with a closed device under ultrasound guidance. Suction was
performed until a negative pressure was obtained. A balanced
crystalloid infusion (Sterofundin, B. Braun Melsungen AG; 2
ml/kg/h IV) and further oxygen supplementation were given.
Clinical status improved. Breathing changed to a costoabdominal
pattern with 32 breaths per minute and pulse oximetry revealed
a SpO2 of 90%. A second thoracic radiograph was made. All lung
lobes appeared rounded with severely reduced volume and were
Abbreviations: DLH, domestic long hair; DSH, domestic short hair;
IV, intravenous; N.a., not approved; PO, per os; RI, reference interval;
SC, subcutaneous.
collapsed and retracted from the parietal pleura. Marked pleural
thickening of all lung lobes was present (Figures 1B,C). Pleural
fibrosis was suggested (9).
Because the lung lobes did not re-expand after
thoracocentesis, iatrogenic pneumothorax was suspected.
Therefore, a second needle thoracocentesis on the left side was
performed. Negative pressure was still present. As a next step,
chest tubes with non-return valves (Heimlich type, LEO-ventil,
Eickemeyer) were placed bilaterally under general anesthesia
(induction with propofol (Narcofol, 10 mg/ml, cp-pharma R©);
maintenance with isoflurane (Isofluran cp, cp-pharma R©);
constant rate infusion with fentanyl (Fentadon R©, 50µg/ml,
Dechra, 0.01 mg/kg/h). During this intervention intermittent
positive pressure ventilation was performed. Chest tubes
were checked for possible leakage by active suction q24h and
thoracic radiographs.
Effusion was diagnosed as exudative chylothorax [cholesterol
effusion: 0.89 mmol/L, cholesterol serum content 3.43 mmol/L;
triglycerides effusion: 6.51 mmol/L, triglycerides serum
content 0.53 mmol/L; cholesterol: triglyceride ratio 0.14
(<1)]. Aerobic and anaerobic bacterial cultures were negative.
Differential cell count showed a neutrophilia (16.3∗109/L;
RI 3.6–12.0∗109/L), a monocytosis (2.3∗109/L, RI 0.0–
1.5∗109/L), and a lymphopenia (0.38∗109/L, RI 0.7–4.8∗109/L).
Laboratory results were consistent with the presence of
chylothorax and chronic inflammation. Abdominal radiographs
and echocardiography were unremarkable. Despite clinical
improvement at day three, there was no re-expansion of the lung
lobes (Figures 1D,E). Computer tomography was performed
under general anesthesia (premedication: 0.2 mg/kg midazolam
(Midazolam-ratiopharm R©, 15 mg/3ml), combination product
of 0.25 mg/kg levomethadonhydrochloride and 0.013 mg/kg
fenpipramidhydhrochloride (L-Polamivet R© 2.5/0.125 mg/ml,
MSD); induction: 4 mg/kg propofol IV (Narcofol, 10 mg/ml, cp-
pharma R©; maintenance: isoflurane (Isofluran cp, cp-pharma R©).
The dog was ventilated with intermittent positive pressure.
Computer tomographic examination revealed a
heterogeneous pleural thickening of multiple lung lobes
suggestive of pleural fibrosis. The right middle lung lobe was
severely atrophic and atelectatic. The remaining lung lobes
were only expanded to 40% on the right side. Left lung lobes
were inflated up to 80%. Mild pleural effusion (right > left)
was present (Figures 2A,B). Findings were consistent with
hydropneumothorax. Contrast-enhanced computer tomography
was unremarkable. Lymphangiography of the thoracic duct
showed no extravasation of contrast medium.
After imaging, right lateral thoracotomy and a single
paracostal approach was performed. To maintain analgesia,
fentanyl (Fentadon R©, 50µg/ml, Dechra) was given as a constant
rate infusion (0.01 mg/kg/h). Presurgical antibiotics were given
(Amox/Clav HEXAL R© i.v. 500/100mg; 12.5 mg/kg IV) and re-
dosed after 90min. Pleural fibrosis presented as withish-tan
material overlaying the lung lobes, preventing their re-expansion.
Thoracic duct ligation, ablation of the chylic cisterna and a
subtotal pericardiectomy were carried out. Due to its highly
abnormal appearance, the middle lung lobe was resected. Both
thoracic sides communicated well, thus only the left chest tube































TABLE 1 | Summary of current literature about fibrosing pleuritis in dogs and cats.
References Number of
patients





One Cat 2-year-old, male DSH
cat
4 weeks Feline infectious peritonitis N.a. Cat died
Chastain
et al. (2)
One Dog 5-year-old, male
Labrador Retriever
Unclear Granulomatous pleuritis, pericardial
effusion: Pasteurella multocida; 8
months later pleural effusion:
Actinomyces bovis
Pericardiocentesis, antibiotics; 8 months later:
thoracocentesis; euthanasia
Euthanasia
Read (3) One Dog 4-year-old, male
Labrador
1 day Traumatic hemothorax, constrictive
pleuritis, prednisone
Decortication Successful outcome; dog 8 months
later clinically unremarkable





Thoracotomy, decortication Euthanasia 5 days after surgery
Fossum et al. (5) Five Dog 2-year-old, sexually
intact mixed-breed dog
6 months Chylothorax, pleural fibrosis, Serratia
spp.
Antibiotic therapy on the basis of sensitivity
testing









18 months Chylothorax, fibrosing pleuritis Antibiotics, needle thoracocentesis, surgical





3 weeks Chylothorax, fibrosing pleuritis Euthanasia Euthanasia
Cat 4-year-old, spayed
DSH cat
2 weeks FeLV positive, lymphoblastic
lymphosarcoma, fibrosing pleuritis
Chemotherapy, needle thoracocentesis,
bilateral placement of perforated plastic
sheetings in the diaphragm







Chylothorax, fibrosing pleuritis Needle thoracocentesis, surgical exploration,
bilateral placement of perforated plastic
sheetings
Cat died 72 h after surgery
Cat 5-year-old, neutered
male DSH cat
9 months Chylothorax, fibrosing pleuritis Surgical exploration, decortication, partial
lobectomy, chest tube placement, pulmonary
edema
Cat died 4 h after surgery










13 weeks Chylothorax, fibrosing pleuritis Periodic thoracocentesis, low-fat diet,
exercise restriction




4 weeks Chylothorax, fibrosing pleuritis Thoracic duct ligation Resolution of chylothorax;
non-chylous effusion; cat died 16
weeks after initial presentation
Cat 4-year-old, male
castrated DSH cat
3 weeks Chylothorax, fibrosing pleuritis Thoracic duct ligation, prednisone Resolution of chylothorax; alive 82


















































































TABLE 1 | Continued
References Number of
patients





30 weeks Chylothorax, fibrosing pleuritis Prednisone Resolution of chylothorax; alive 69
weeks after initial presentation
Cat 5-year-old, female
spayed DSH
17 weeks Chylothorax, fibrosing pleuritis Periodic thoracocentesis, low-fat diet,
exercise restriction




5 weeks Chylothorax, fibrosing pleuritis Thoracic duct ligation, prednisone Resolution of chylothorax;
non-chylous effusion; euthanasia 8
weeks after initial presentation
Cat 4-year-old, male
castrated DSH
9 weeks Chylothorax, fibrosing pleuritis Thoracic duct ligation, prednisone Resolution of chylothorax:
non-chylous effusion; euthanasia 30
weeks after initial presentation
Cat 12-year-old, female
spayed DSH cat
1 day Chylothorax, fibrosing pleuritis Thoracic duct ligation, prednisone, passive
peritoneal lavage
Resolution of chylothorax;
non-chylous effusion; euthanasia 3
weeks after initial presentation
Fossum et al. (7) Three Cat N.a. 2 weeks to 1 year Chylothorax, severe fibrosing pleuritis Thoracotomy with thoracic duct ligation,
pericardiectomy, two cats received
decortication, complications: two cats had
pneumothorax, one cat had tracheal tear
Pneumothorax resolved in both cats
with decortication; remaining cats
unclear
Two Cat N.a. 2 weeks to 1 year Chylothorax, moderate fibrosing
pleuritis
One Dog N.a. 2 weeks to 1 year Chylothorax, mild fibrosing pleuritis Thoracotomy with thoracic duct ligation,
pericardiectomy
Chylothorax resolved
Lafond et al. (8) One Cat 6-year-old, spayed
female Himalayan cat
2 months Chylothorax, constrictive pleuritis Omentalization of the thorax, partial
decortication; complication: transient
pneumothorax
Full recovery; clinically normal 13
months after surgery
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FIGURE 1 | (A) Day 1: Lateral left sided thoracic radiograph view: Markedly
increased soft- tissue opacity with completely silhouetted cardiac silhouette
and retracted lung lobes due to a severe pleural effusion. (B,C) Day 1:
Lateral left sided and ventrodorsal thoracic radiograph view: After needle
thoracocentesis lung lobes were severely rounded and expanded to ∼40%.
Heterogenous pleural thickening is present. The heart is detached from the
sternum. An iatrogenic pneumothorax was suspected. (D,E) Day 3: Lateral left
sided and ventrodorsal thoracic radiograph view: Chest tubes are placed
bilaterally. Lung lobes are re-expanded to 80% on the left and to 60% on the
right side. Sternal lymphnode (asterisk) is prominent and a precardial
mass-effect (arrow) is seen. The latter is suggestive for fibrotic tissue.
with a non-return valve (Heimlich type, LEO-ventil, Eickemeyer)
was left. Chest tube functionality was assessed clinically, by
measurement of produced fluid, active suction q24h and by
thoracic radiographs (Figures 3A,B).
Bacterial culture of the resectedmiddle lung lobe was negative.
Histology revealed severe, chronic-active, proliferative, and
beginning granulomatous pleuritis. Additionally, a moderate to
severe subacute to chronic, purulent proliferative, and beginning
fibrotic pericarditis with predominantly fibrotic deposits on
the serosal lining was diagnosed. A sub-acute to chronic
granulomatous, partially demarcated coagulative necrosis of the
parenchyma of the middle lung lobe with partially massive and
predominantly resorbed hemorrhages, thrombosed vessels, and
micro-fragmented bronchi were detected. With periodic acid-
Schiff reaction no foreign material, fungal, or parasitic structures
were detected (11). Ziehl-Neelsen staining was negative. These
findings suggested that the sterile inflammatory process had
occurred for at least several weeks, likely much longer. Idiopathic
chylothorax with granulomatous pleuritis and highly atelectatic
middle lung lobe was diagnosed.
Further patient management included a continuous rate
infusion with balanced crystalloids and analgesics (2 ml/kg/h
Sterofundin, B. Braun Melsungen AG, 0.002 mg/kg/h fentanyl
(Fentadon, 50µg/ml, Dechra), 0.12 mg/kg/h ketamine
(Anesketin, 100 mg/ml, Dechra), and 0.2 mg/kg/h lidocaine
(LidoCARD, 2%, B. Braun) for 2 days (12). During inpatient
treatment the dog was clinically unremarkable. Starting at day
three after thoracotomy meloxicam (Metacam, Boehringer
Ingelheim; initially 0.2 mg/kg SC, q24h then 0.1 mg/kg, q24h
PO) was administered for 4 months. During this time no
gastroprotective agents were given. Amoxicillin clavulanate (12.5
mg/kg q12h PO) was administered for 3 days until bacterial
culture confirmed negativity. The dog tolerated meloxicam well
and did not show any side effects.
Lungs re-expanded to ∼80% 6 days after surgery
(Figures 3A,B). Ten days after thoracotomy, the remaining
chest tube was removed. The dog was discharged 7 h after chest
tube withdrawal with a normal breathing pattern and a SpO2
of 98%. Clinical, radiographic and ultrasonographic follow-up
examinations were performed every two to 14 days within the
first two months. Further controls were carried out 2, 4, 6,
and 15 months later. Pleural effusion persisted for 4 months
(Figures 3C–H). Seven days postoperatively effusion specimen
was generated from the chest tube. Effusion was diagnosed as
non-chylic, non-septic, serosanguineous exudate (cell count:
16,146∗109/L; protein content: 14 g/L; triglyceride effusion:
0.21 mmol/L; triglyceride serum: 0.70 mmol/L). On day 24,
modified transudate (cell count: 3,566∗109/L; protein content:
28 g/L) and 3.5 months later transudate was present (cell count:
1,698∗109/L; protein content: 13 g/L). Both effusion specimens
were obtained by needle thoracocentesis. Lungs were inflated
to ∼95% 4 months after initial presentation. Fifteen months
post initial presentation, complete re-expansion of the lungs
was seen. Pleural effusion was evident neither on radiographs
(Figures 3I,J) nor by ultrasonography. Mild pleural fibrosis
persisted. Material of soft-tissue opacity overlaid the cardiac
silhouette. Fine needle aspiration was performed, and fibrotic
tissue was suggested. During the whole observation period the
dog was clinically unremarkable. A telephone conversation with
the owners 5 years later revealed that the dog is clinically healthy.
DISCUSSION
Pleural fibrosis develops when pleural effusions irritate the
lungs’ pleura. Fibrin formation is promoted by the release of
chemokines and cytokines (e.g., TGF-β and TNF-α) (13–17).
Frontiers in Veterinary Science | www.frontiersin.org 5 August 2019 | Volume 6 | Article 278
Rehbein et al. Unexpandable Lungs in a Dog
FIGURE 2 | (A,B) Day 3: Computer tomography: Heterogenous pleural thickening of multiple lung lobes is seen. The right middle lung lobe is severely atrophic and
atelectatic (asterisk). The remaining lung lobes are expanded to ∼40% on the right side. Left lung lobes are nearly completely re-expanded on the left side. Mild pleural
effusion is present (right > left).
Although some aspects of pathophysiology are already known,
it is still unclear why some patients develop pleural fibrosis and
others do not (13).
Various causes of pleural fibrosis in dogs are described. One
dog suffered from granulomatous pleuritis, which is a form
of pleural fibrosis (18). Bacterial culture detected Pasteurella
multocida within the pericardial effusion. Antibiotic therapy
was introduced but 9 months later Actinomyces bovis was
detected in the thoracic cavity. Due to guarded prognosis the
animal was euthanized (2). Another dog with pleural fibrosis
was infected with Serratia spp. after thoracocentesis. Despite
adequate antibiotics, the dog died 2 days after initial presentation
(5). Further known causes of pleural fibrosis in dogs are
presence of chylothorax (n = 3) and traumatic hemothorax
(n = 1) (3, 5, 7). In cats, chylothorax is the most common
cause of pleural fibrosis (n = 20; Table 1). One case each was
described with feline infectious peritonitis and lymphoblastic
lymphoma (FeLV positive) (Table 1). In the present case, pleural
alterations hindered the lungs to completely re-expand and were
caused by chylic effusion. Neither by bacterial culture nor by
histopathological examination infectious agents were detected.
Therefore, idiopathic chylothorax was diagnosed (9).
In general, pneumothorax can be classified in dogs as
traumatic (e.g., dog bite), spontaneous (e.g., blebs or bullae),
or iatrogenic (e.g., after thoracocentesis). Spontaneous
pneumothorax is defined as a non-traumatic and closed
pneumothorax. It can even occur after laparoscopic ovariectomy
(19, 20). All these kinds of pneumothorax are characterized by
the presence of supraatmospheric intrapleural pressure (19). In
contrast, negative intrapleural pressure is seen in a state called
pneumothorax ex vacuo, which is associated in human medicine
with an entity called trapped lungs. This entity is one of two
different types of unexpandable lungs. This condition occurs in
patients with remote pleural inflammation due to infections,
hemothorax, pneumothorax, uremia, rheumatoid pleurisy, or
thoracic interventions. Negative intrapleural pressure hinders
the lungs to re-expand. Effusion is of transudative quality.
Patients are mostly asymptomatic. In contrast, lung entrapment
is associated with an active pleural inflammation due to active
pleural infections or malignant processes. Patients are presented
with dyspnea and pleurisy. Intrapleural pressure can be positive
and pleural effusions are exudative (10, 21). In human medicine,
pleural manometry is recommended to estimate intrathoracic
pressure and to distinguish between these two entities (22).
However, a clear distinction is difficult. One study proposed
that lung entrapment leads to pleural fibrosis. Subsequently,
trapped lung can develop, if the initial insult is resolved
(21). It is likely that this occurred in our dog. Actively
formed chylothorax led to lung entrapment, which resulted
after successful surgery in trapped lung with passively formed
transudate and pneumothorax ex vacuo. Manometry was not
performed, because it was unavailable.
To what extent middle lung lobe atrophy and necrosis
contributed to lung entrapment or trapped lung is questionable.
Two scenarios are possible. First scenario is that alterations
of the middle lung lobe resulted from lung lobe torsion as a
consequence of severe pleural effusion or trauma (23). A second
possibility is that middle lung lobe atelectasis resulted from
increased pressure on lungs’ parenchyma due to severe pleural
effusion (24). Both options could not be proven by computer
tomography or by pathohistological examination.
Patients suffering from pneumothorax ex vacuo may be
mostly asymptomatic. This is consistent with our case and
underlines the presence of trapped lung (10). In contrast,
previously reported canine and feline cases described that
patients suffered mostly from severe respiratory distress
(5, 10, 13). This would support the assumption that
lung entrapment overweighed in these cases. However, a
distinction between trapped lungs and lung entrapment was
not done.
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FIGURE 3 | (A,B) Day 6: Lateral left sided and ventrodorsal thoracic
radiograph view: Lung lobes re-expanded to 80% on the left and right side.
(Continued)
FIGURE 3 | Titanum clips are present on the height of the right middle lung
lobe. On the left side a chest tube is placed. Pleural thickening is present in all
remaining lung lobes. Cardiac silhouette is slightly detached from the sternum.
(C,D) Day 18: Lateral left sided and ventrodorsal thoracic radiograph view:
Moderate increased soft- tissue opacity with partially silhouetted cardiac
silhouette. Lung lobes are mildly retracted (90% re-expansion). On the left side
a chest tube is present. (E,F) Day 24: Lateral left sided and ventrodorsal
thoracic radiograph view: After needle thoracocentesis: Lung lobes are
expanded to ∼80% on the left and 70% on the right side. Heterogenous
pleural thickening of the remaining lung lobes is seen. (G,H) 4 months later:
Lung lobes are re-expanded to 95% on both thoracic sides. Mild pleural
fibrosis is present. Mild fluid accumulation is seen. (I,J) 15 months later:
Lateral left sided and ventrodorsal thoracic radiograph view: Complete
re-expansion of all lung lobes. Mild pleural fibrosis is still present. Material of
soft-tissue opacity is seen overlaying the cardiac silhouette. Fine needle
aspiration revealed the presence of fibrotic tissue. Fluid accumulation could be
excluded by ultrasonography.
The main goal should be to rule out underlying disease
processes. Successful treatment hinders further irritations
of the pleura and thus progression of fibrin formation
(7, 25). As a standard, complete blood cell count, serum
biochemistry, effusion analysis including measurements of
triglycerides and cholesterol in comparison with serum values,
cytology, aerobic and anaerobic culture, thoracic radiographs,
and echocardiography should be performed (26). Radiological
findings can be suggestive for pleural fibrosis. One study
proposed, that two out of three following radiological findings
should be present: first pleural thickening, second rounded lung
lobes and/or third persistently retracted lung lobes (6). All these
alterations were detectable in our dog. Computer tomography
is helpful to outline the degree of pleural fibrosis, degree of
lung’s expansion, course and branching of the thoracic duct, or
malignant processes (27). Intra operative presentation is also
indicative for pleural fibrosis. Withish-tan material overlays the
lungs with variable degrees of adhesion to other intra-thorax
structures (5, 6). Despite the presence of fibrous peel surrounding
the lungs’ parenchyma, it was certainly advantageous for our
patient’s outcome that no further adhesions were present. To
confirm a diagnosis and also to exclude possible underlying
diseases, biopsies and pathohistological analysis should be
carried out.
In patients with pneumothorax ex vacuo, chest tube placement
is not appropriate, because this kind of pneumothorax results
from a re-equilibration of intra- and extra-pulmonary pressure
(10). Decortication is only recommended in humans and
pets with severe respiratory distress, because clinical signs
can be fatal. Pneumothorax, tracheal tears, hemorrhages, re-
expansion pulmonary edemas, or death can occur (5, 7). Our
patient benefited of chest tube placement, because further
accumulation of chylic effusion and lung entrapment was
reduced. Decortication was not performed, because clinical signs
and intraoperative findings were not severe.
To inhibit further inflammation, glucocorticoids were given
in cats with variable outcomes (6). In humans, these are
only indicated and successful in rheumatoid pleurisy (13). No
other inflammatory drugs are described in clinical patients.
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Experimental studies in mice and rats showed that the NSAID
meloxicam had anti-fibrotic properties in kidneys, liver, lung, and
pleurisy (28–31). Glucocorticoids were not given in our patient,
because wound healing could be delayed, and risk of infection can
be increased. Side-effects like polyuria, polydipsia, and panting
can also be severe in some dogs. Therefore, meloxicam was given
for 4 months until transudative effusion was seen. Pneumothorax
ex vacuo resolved, but mild pleural fibrosis persisted. After
withdrawal of meloxicam pleural effusion did not reoccurred.
It is likely that meloxicam encouraged pleural remodeling and
lung expansion, although complete resolution of pleural fibrosis
was not achieved. However, NSAIDs should be used cautiously.
Gastrointestinal signs like vomitus and diarrhea are the main
side effects of the COX-1 sparing meloxicam. The incidence
of adverse reactions is inconsistently described (32). Clinical
signs were obvious in up to 25% of patients with varying
treatment durations (1–84 days) and dosages (33–37). Thus,
comparability of data is difficult. However, an increased duration
of meloxicam administration is not necessarily associated with
a higher incidence of side effects. Administration up to 84 days
resulted in adverse effects in 3.4% of dogs, whereas a treatment
duration of 28 days in another study caused side effects in 25%
of dogs (34, 37). The longest duration of administration was
reported in a safety study of transmucosalmeloxicam application.
Meloxicam was given 26 weeks with up to the fifths time of
maximum proposed dosage. Gastrointestinal signs were mainly
obvious at higher dosages (38). To ensure drug compatibility in
our dog periodic clinical, hematology and blood biochemistry
examinations were performed. Additionally, the owners were
instructed to closely monitor the dog’s behavior, appetite and
feces. Currently, prophylactic administration of gastroprotective
drugs was not proven to be beneficial, if NSAIDs were given
(39). Our dog did not show any obvious side effects, thus, no
gastroprotective agents were administered.
Prognosis in dogs and cats with pleural fibrosis is generally
poor. In the veterinary literature a high mortality rate is reported.
This contrasts with our patient, who had an excellent outcome. It
is evident that further investigations are necessary to characterize
canine lung trapping and entrapment lungs in detail. The
effectiveness of meloxicam in canine granulomatous pleuritis
should be ruled out in further clinical studies. However, results
of this presented case are promising.
CONCLUDING REMARKS
To the authors’ knowledge, this is the first case report with
pneumothorax ex vacuo caused by sterile granulomatous
pleuritis and chylothorax in a dog with an excellent
clinical outcome.
Meloxicam seemed to encourage pleural remodeling and lung
expansion, although complete resolution of pleural fibrosis was
not achieved.
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